RobertTO'DonnellMD

Professor, Internal Medicine, UC, Davis School of Medicine

Dr. O'Donnell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2279 45th St
Sacramento, CA 95817
Phone+1 916-734-5959

Fax+1 916-703-5265

University of California Davis HealthFellowship, Hematology and Medical Oncology, 1990 - 1993
University of California Davis HealthResidency, Internal Medicine, 1987 - 1990
Loyola University Chicago Stritch School of MedicineClass of 1987

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

PubMed

5 citations
Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells.
Jose Sandoval, Alexey Tomilov, Sandipan Datta, Sonia A. Allen, Robert T. O'Donnell
Pharmaceuticals. 2020-11-24
10 citations
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia
Benjamin Tomlinson, Joseph Tuscano, Mehrdad Abedi, Jeanna L Welborn, Mili Arora
American Journal of Hematology. 2019-11-01
12 citations
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
Anthony B. El-Khoueiry, Robert T. O'Donnell, Thomas J. Semrad, Philip C. Mack, Suzette Blanchard
Cancer Chemotherapy and Pharmacology. 2018-03-08

Immunoliposomal Therapy Of Non-Hodgkin'S LymphomaVeterans Affairs2012
Phasei/Ii Clinical Trial Of Hhb22.7 Anti-Cd22 Monoclonal Antibody For LymphomaNational Cancer Institute2006–2007
Combined Modality Radioimmunotherapy For Nonhodgkins LymphomaNational Cancer Institute1999–2002